Long-acting injectable antipsychotic uptake reveals adherence-versus-access gap in schizophrenia

Reading the signal

Long-acting injectable (LAI) antipsychotics provide sustained antipsychotic effect over weeks to months from a single injection, addressing the adherence-driven relapse cycle that characterises schizophrenia management with oral therapy. The clinical and outcome data:

• LAI use is associated with substantially lower hospitalisation and relapse rates than oral antipsychotic use in eligible patients
• Quality-of-life and functional-outcome data favour LAI use in patients with adherence challenges
• LAI is endorsed by major guidelines for patients with documented adherence issues, recent first episodes, or multiple-relapse histories

Despite this, real-world uptake of LAI is substantially below the eligible-population estimate across major markets. The structural reasons:

• Access infrastructure: LAI administration requires injection-capable clinical settings (community mental health centres, specialist clinics, primary care with injection capacity). The infrastructure exists but is geographically uneven
• Prescriber inertia: Oral antipsychotic prescribing is the default. Switching to LAI requires explicit prescriber action and patient consent, and the operational steps create friction
• Patient-pathway complexity: Insurance authorisation, injection scheduling, side-effect management, and transition from inpatient to outpatient care all create friction in LAI uptake
• Stigma considerations: Some patients perceive LAI as more stigmatising than oral therapy; the perception varies but is real

Commercial implications

For sponsors of LAI antipsychotic assets and adjacent psychiatric pipeline:

1. Access infrastructure investment is the commercial growth axis. Sponsors that invest in clinic-level injection capacity, specialist-nurse training, and patient-pathway support unlock substantial commercial volume
2. The dosing-frequency conversation is now active within the LAI class. Once-monthly, twice-yearly, and other extended-duration formulations are differentiating commercially in ways the established class did not
3. Adjacent psychiatric LAI pipeline (LAI mood stabilisers, LAI substance-use disorder mechanisms) is inheriting both the access infrastructure and the prescriber-engagement learnings

What we are watching

• Late-stage extended-duration LAI antipsychotic programs and the rate of reduced-frequency formulation entry
• Real-world LAI uptake patterns in markets with active access-infrastructure investment
• Adjacent LAI pipeline (mood stabilisers, addiction medicine, novel mechanisms in LAI form) and how it leverages the schizophrenia LAI infrastructure